Table 2.

Response after dose increase in patients with imatinib failure

Outcome	Total, n = 84	Cytogenetic failure, n = 63	Hematologic failure, n = 21	P
Cytogenetic response, n (%)
Any	50 (60)	47 (75)	3 (14)	< .001
Partial*	10 (14)	8 (16)	2 (10)	.77
Complete	34 (40)	33 (52)	1 (5)	< .001
% 2-year
EFS	57	65	36	< .001
FFS	29	38	5	< .001
TFS	73	80	51	.004
OS	84	90	67	< .001

EFS indicates event-free survival; FFS, failure-free survival; TFS, transformation-free survival; and OS, overall survival.

^*Only patients (n = 71) not in MCyR at the time of imatinib dose escalation were evaluable.